CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.10M | 3.51M | 38.34M | 38.05M | 37.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.10M | 3.51M | 38.34M | 38.05M | 37.68M |
| Cost of Revenue | 482.82M | 498.29M | 443.21M | 420.51M | 437.76M |
| Gross Profit | -478.71M | -494.78M | -404.88M | -382.46M | -400.08M |
| SG&A Expenses | 71.43M | 73.54M | 73.27M | 73.76M | 74.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 554.25M | 571.83M | 516.48M | 494.26M | 512.08M |
| Operating Income | -550.14M | -568.32M | -478.14M | -456.21M | -474.40M |
| Income Before Tax | -565.17M | -577.97M | -484.58M | -463.82M | -381.69M |
| Income Tax Expenses | 3.36M | 3.63M | 3.72M | 3.98M | 3.97M |
| Earnings from Continuing Operations | -568.53 | -581.60 | -488.30 | -467.80 | -385.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -568.53M | -581.60M | -488.30M | -467.80M | -385.66M |
| EBIT | -550.14M | -568.32M | -478.14M | -456.21M | -474.40M |
| EBITDA | -531.08M | -548.84M | -459.48M | -437.25M | -455.24M |
| EPS Basic | -6.21 | -6.51 | -5.58 | -5.42 | -4.52 |
| Normalized Basic EPS | -3.17 | -3.36 | -2.77 | -2.67 | -2.79 |
| EPS Diluted | -6.22 | -6.52 | -5.59 | -5.43 | -4.52 |
| Normalized Diluted EPS | -3.17 | -3.36 | -2.77 | -2.67 | -2.79 |
| Average Basic Shares Outstanding | 369.70M | 359.58M | 349.78M | 343.71M | 341.56M |
| Average Diluted Shares Outstanding | 369.70M | 359.58M | 349.78M | 343.71M | 341.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |